Which flu vaccine packs a bigger punch for people with HIV?
NCT ID NCT07644546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will compare two enhanced flu vaccines—one with an adjuvant (MF59) and one with a higher dose—in 350 adults living with HIV. The goal is to see which vaccine triggers a stronger immune response. Participants will receive one shot and have their antibody levels checked after 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MF59-adjuvanted influenza vaccine and high-dose influenza vaccine
- What this could lead to
- If this trial succeeds, it could show which flu vaccine works best for people with HIV, leading to better protection during flu season.
- What could go wrong
- This trial hasn't started yet and is relatively small (350 people). Results may not apply to all people with HIV, and the vaccines may not prevent infection entirely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia
- Could intense workouts reverse cognitive decline in older HIV patients?